US FDA Commissioner Race: Transparency Comes To Forefront With Study Of Refuse-To-File Letters
Executive Summary
Of the two main contenders to lead FDA, Josh Sharfstein is seen as much more likely to open up review decisions to public scrutiny, while Janet Woodcock might be a vote for the status quo and more deferential to industry concerns.
You may also be interested in...
Woodcock Has Big, Quiet Supporter In Her Bid For US FDA Commissioner
Industry groups, along with many rare disease and patient advocacy groups, appear behind the acting commissioner getting the permanent position.
US FDA's Integrated Review Doc: Industry Says Don't Lose The Detail
Stakeholders, some worried about "groupthink," tell the US FDA they want the individual discipline comments on newly approved drugs to stay in action packages because of the valuable insights they provide.
US FDA May Scrap Clinical Study Report Disclosure For New Drug Approvals
The pilot project former Commissioner Gottlieb championed found only one sponsor interested in participating.